Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.

Publication ,  Journal Article
Dent, SF; Morse, A; Burnette, S; Guha, A; Moore, H
Published in: Curr Oncol Rep
August 27, 2021

PURPOSE OF REVIEW: HER2-targeted therapies have led to improved clinical outcomes in early and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted therapy in early and advanced BC, our current knowledge of cardiotoxicity of novel HER2-targeted therapies, and propose a cardiac monitoring (CM) strategy for this population. RECENT FINDINGS: Long-term data from studies with HER2-targeted therapy in the adjuvant setting have failed to demonstrate an increase in cardiotoxicity over time, and rates of cardiotoxicity seen with novel HER2 agents remain low. Despite over a decade of experience with HER2-targeted therapy, CM in clinical practice is inconsistent in patients with early BC and almost non-existent in advanced BC. Long-term follow-up of clinical trials with HER2-targeted agents in early and advanced BC has failed to demonstrate increased rates of cardiotoxicity over time, attesting to the long-term safety of this class of drugs for the majority of patients, although the long-term cardiac safety of newer HER2 agents in the non-clinical trial setting is largely unknown. We propose CM incorporating clinical history, cardiac imaging, and biomarkers.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Oncol Rep

DOI

EISSN

1534-6269

Publication Date

August 27, 2021

Volume

23

Issue

11

Start / End Page

128

Location

United States

Related Subject Headings

  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Molecular Targeted Therapy
  • Immunoconjugates
  • Humans
  • Female
  • Clinical Trials as Topic
  • Cardiotoxicity
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dent, S. F., Morse, A., Burnette, S., Guha, A., & Moore, H. (2021). Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. Curr Oncol Rep, 23(11), 128. https://doi.org/10.1007/s11912-021-01114-x
Dent, Susan F., Amber Morse, Sarah Burnette, Avirup Guha, and Heather Moore. “Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.Curr Oncol Rep 23, no. 11 (August 27, 2021): 128. https://doi.org/10.1007/s11912-021-01114-x.
Dent SF, Morse A, Burnette S, Guha A, Moore H. Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. Curr Oncol Rep. 2021 Aug 27;23(11):128.
Dent, Susan F., et al. “Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.Curr Oncol Rep, vol. 23, no. 11, Aug. 2021, p. 128. Pubmed, doi:10.1007/s11912-021-01114-x.
Dent SF, Morse A, Burnette S, Guha A, Moore H. Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. Curr Oncol Rep. 2021 Aug 27;23(11):128.
Journal cover image

Published In

Curr Oncol Rep

DOI

EISSN

1534-6269

Publication Date

August 27, 2021

Volume

23

Issue

11

Start / End Page

128

Location

United States

Related Subject Headings

  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Molecular Targeted Therapy
  • Immunoconjugates
  • Humans
  • Female
  • Clinical Trials as Topic
  • Cardiotoxicity